All In MedTech

Device Trial Radar · NCT06073301

AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF

Comparison of Treatment With Acellular Fish Skin (AFS) to Acellular Human Cadaver Allograft (AHC) in the Treatment of Necrotizing Fasciitis (NF)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

6

Actual

Start

Aug 1, 2023

Primary completion

Aug 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Kerecis Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Joseph M. Still Research Foundation, Inc.
First posted
Oct 10, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Necrotizing Fasciitis (NF) is a potentially life-threatening soft tissue infection. This study is comparing acellular fish skin graft (AFS) to standard of care allograft (AHC) in the treatment of NF. The purpose of this study is to compare clinical outcomes and time until autograft take in patients that were treated with AHC or AFS prior to permanent autografting to treat NF.

Conditions

  • Necrotizing Fasciitis

Interventions

  • Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)Device

    Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.

  • Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)Other

    Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary endpoint: To compare the time from first application of study product to time of autografting between the two study groups.Time frame: 9 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Joseph M. Still Research Foundation

    Augusta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.